Results 31 to 40 of about 1,199 (132)

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Polivalenza del ridere: i casi omerici di ἄσβεστος γέλως

Erga-Logoi
Polyvalence of laughter: Homeric cases of ἄσβεστος γέλως  The present article intends to analyze the three different Homeric cases of ἄσβεστος γέλως (Il. I 599; Od. VIII 326; XX 346).
Fabrizio Pasqualini
doaj   +1 more source

Anemia and Patient‐Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real‐World Observational Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement‐mediated hemolysis, thrombosis, bone marrow failure, and anemia. Although current treatments improve outcomes, patients still experience hemolysis and could remain anemic with a negative impact on quality of life (QoL).
Esther Natalie Oliva, Antonio M Risitano, Eros Di Bona, Alessandro Maria Vannucchi, Ilaria Maria Dellfino, Antonio De Vivo, Valentina Giai, Rosario Notaro, Giuseppe Iannì, Eloise Beggiato, Simona Sica, Gaetano La Barba, Sneha Balakrishnan, Joanna Large, Tanuja Thavarajah, Simona Raso, Raffaele Fontana, Wilma Barcellini, Bruno Fattizzo, Roochi Trikha, Luana Marano, Jens Panse, Austin G Kulasekararaj   +22 more
wiley   +1 more source

Amat bonus otia Daphnis (Verg. Ecl. V 61). L’ideale della concordia nella Ecloga V

Erga-Logoi
Amat bonus otia Daphnis (Verg. Ecl. V 61). The ideal of concordia in Eclogue V The concept of concordia plays a key role in the political debate among Virgil’s contemporaries. Virgil himself highlights the role of discordia in Ecl.
Giacomo Dettoni
doaj   +1 more source

A Real‐World Cross‐Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified

Clinical and Translational Allergy, Volume 16, Issue 7, July 2026.
ABSTRACT Background A variety of clinical signs and symptoms have been described in patients suspected of having mast cell activation syndrome (MCAS), however, symptom patterns and linked organ systems were not yet described. Methods This cross‐sectional online survey included adults with physician‐diagnosed self‐assessed or suspected MCAS between June
Annika Gutsche, Thomas Buttgereit, Rüdiger Buchkremer, Jens Panse, Nina Kreddig, Olga Ptock, Stephanie Roll, Weronika Grabowska, Felix Aulenbacher, Martin Metz, Polina Pyatilova, Pascale Salameh, Manuel P. Pereira, Frank Siebenhaar   +13 more
wiley   +1 more source

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun‐ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj   +15 more
wiley   +1 more source

Digitizing collections to unlock the full potential of palynology: A case study with the Smithsonian palynology collection

PLANTS, PEOPLE, PLANET, Volume 8, Issue 4, Page 1116-1131, July 2026.
Large palynological collections have been built over decades and contain vital information. However, they are often difficult to access and use effectively. What is the point of having such collections if they are not fully utilizable? To solve this problem, we digitized the Smithsonian palynological collection using both light and confocal microscopy.
Carlos Jaramillo, Surangi W. Punyasena, Daurys de Alba, Roxana Alveo, Angelica Arcila, Jorge Bermudez, Jonatan Bustos, Dayenari Caballero‐Rodriguez, Karen Cardenas, David Caro, Francy Carvajal, Ivonne Marcela Castañeda, Shara Chaves, Carlos D'Apolito, Andres Diaz‐Jaramillo, Laura Diaz, Luisa Gomez, Mauricio León‐Carreño, Paula Lopera, Maria Alejandra Lopez, Priscila Lopez, Luke Mander, Jhonatan Martínez Murcia, Carlos Moreno, Enrique Moreno, Enrique Neyra, Brenda Orosco, Jhon Ortiz, Natalia Ossa, Natalia Ovalle, Carolina Ovalle, Angelo Plata, Ingrid Romero, Bruno Scudeiro, Silane A. F. da Silva Caminha, Axel Tejada‐Fajardo, Vinicius Do Valle, Thiago Wood   +37 more
wiley   +1 more source

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti‐C5 often experience extravascular hemolysis with anemia. Iptacopan, the first oral proximal complement inhibitor targeting factor B, has shown efficacy and safety in PNH patients. APPULSE‐PNH (NCT05630001), a phase 3b, single‑arm, open‐label trial, enrolled adult patients with PNH
Austin Kulasekararaj, Flore S. de Fontbrune, Anna Gaya, Ilene Weitz, David J. Kuter, Bhumika J. Patel, David J. Araten, Abhay Singh, Jun H. Jang, Richard J. Kelly, Eros Di Bona, Michael Loschi, Vinod Pullarkat, Jörg Schubert, Rosario Notaro, Mustafa N. Yenerel, Joan Beckman, Nicolas Blin, Irina Murakhovskaya, Jens Panse, Eloy Roman, Alexander Röth, Hubert Schrezenmeier, Srinivas Tantravahi, Régis P. de Latour, Navin Mahajan, Luca Monaco, Tao Ding, Tomasz Lawniczek, Philippe Ferber, Marion Dahlke, Antonio M. Risitano   +31 more
wiley   +1 more source

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL‐AVA 3.5 study

British Journal of Haematology, Volume 208, Issue 6, Page 2185-2193, June 2026.
Summary Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA).
Caroline Piatek, Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland   +8 more
wiley   +1 more source